Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists

被引：162

作者：

Lange, JHM ^{[1
]}

Kruse, CG ^{[1
]}

机构：

[1] Solvay Pharmaceut, Res Labs, NL-1381 CP Weesp, Netherlands

来源：

DRUG DISCOVERY TODAY | 2005年 / 10卷 / 10期

关键词：

D O I：

10.1016/S1359-6446(05)03427-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The proven clinical efficacy of the CB1 cannabinoid receptor antagonist rimonabant in both obesity and smoking cessation and its therapeutic potential in other disorders has given a tremendous impetus to the discovery of novel CB1 antagonists. The number of disclosed patents wherein novel chemical entities having CB1 antagonistic or inverse agonistic properties have been claimed has exploded. Besides novel compound classes that were identified in screening, rational medicinal chemistry approaches such as conformational constraint and scaffold hopping have been successfully applied. CB1 receptor modelling has provided insight into crucial receptor-ligand interaction points thereby leading to a general CB, inverse agonist pharmacophore model.

引用

页码：693 / 702

页数：10

共 107 条

[31] Cannabinoids: Mechanisms and therapeutic applications in the CNS [J].

Drysdale, AJ ;

Platt, B .

CURRENT MEDICINAL CHEMISTRY, 2003, 10 (24) :2719-2732

[32] Potent imidazole and triazole CB1 receptor antagonists related to SR141716 [J].

Dyck, B ;

Goodfellow, VS ;

Phillips, T ;

Grey, J ;

Haddach, M ;

Rowbottom, M ;

Naeve, GS ;

Brown, B ;

Saunders, J .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) :1151-1154

[33]

Fernandez Jose R, 2004, Curr Opin Investig Drugs, V5, P430

[34] Possible involvement of the endocannabinoid system in the actions of three clinically used drugs [J].

Fowler, CJ .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (02) :59-61

[35] Structure elucidation of a novel ring-constrained biaryl pyrazole CB, cannabinoid receptor antagonist [J].

Francisco, MEY ;

Burgess, JP ;

George, C ;

Bailey, GS ;

Gilliam, AF ;

Seltzman, HH ;

Thomas, BF .

MAGNETIC RESONANCE IN CHEMISTRY, 2003, 41 (04) :265-268

[36] Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) [J].

Francisco, MEY ;

Seltzman, HH ;

Gilliam, AF ;

Mitchell, RA ;

Rider, SL ;

Pertwee, RG ;

Stevenson, LA ;

Thomas, BF .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (13) :2708-2719

[37] ISOLATION, STRUCTURE, AND PARTIAL SYNTHESIS OF AN ACTIVE CONSTITUENT OF HASHISH [J].

GAONI, Y ;

MECHOULAM, R .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1964, 86 (08) :1646-+

[38] 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor [J].

Hanus, L ;

Abu-Lafi, S ;

Fride, E ;

Breuer, A ;

Vogel, Z ;

Shalev, DE ;

Kustanovich, I ;

Mechoulam, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (07) :3662-3665

[39] HU-308:: A specific agonist for CB2, a peripheral cannabinoid receptor [J].

Hanus, L ;

Breuer, A ;

Tchilibon, S ;

Shiloah, S ;

Goldenberg, D ;

Horowitz, M ;

Pertwee, RG ;

Ross, RA ;

Mechoulam, R ;

Fride, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (25) :14228-14233

[40] Recent advances in the cannabinoids [J].

Hertzog, DL .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (10) :1435-1452

← 1 2 3 4 5 6 7 8 9 10 →